HPM_442_F_TgCHG_1128
|
|
|
- ふじよし かくはり
- 9 years ago
- Views:
Transcription
1 3M TM Chlorhexidine Gluconate IV Securement Dressings Tegaderm TM CHG Support CRBSI Prevention
2 TegadermTM CHG Dressing 2w/w% 60% N. Safdar, Intensive Care Med
3 Guideline Centers for Disease Control and Prevention CDC Healthcare Infection Control Practice Advisory Committee HICPAC, Guideline for the Prevention of Intravascular Catheter-Related Infections 2011, , ,
4 7 days 5 10mm Mean Log Count log(10)cfu/cm M.H.BashirAmerican Journal of Infection Control Zone of Inhibition Beyond Gel Pad(MM) Days Debra L SchwabInfusion Nurses Society INS in Vitro test w/w% 0% 100% 200% Change
5 GRAM POSITIVE ZOI GRAM NEGATIVE & YEAST ZOI AVERAGE ZONE GEL DIAMETER 24 MM faecalis Wound Isolate #23 faecalis faecalis 7080 faecium(mdr)51559 faecium(vre) Corynebacterium diphtheriae aureus Nasal Isolate #849 aureus (MRSA)USA 800 aureus (MRSA)USA 500 aureus (MRSA)USA 600 epidermidis epidermidis epidermidis epidermidis epidermidis epidermidis(mrse) epidermidis(mrse) nasal isolate #492 aureus aureus (MRSA/GRSA)33592 aureus (MRSA)USA 100 aureus (MRSA)USA 300 AVERAGE ZONE Acinetobacter baumannii GEL DIAMETER MM Candida albicans Candida albicans Proteus mirabilis Proteus mirabilis Escherichia coli Klebsiella pneumoniae Klebsiella pneumoniae Enterobacter cloacae Acinetobacter baumannii BAA-747 Acinetobacter baumannii BAA-747 Pseudomonas aeruginosa Pseudomonas aeruginosa Pseudomonas aeruginosa Pseudomonas aeruginosa 9027 Pseudomonas aeruginosa J. P. Hensler Europian Congress of Clinical Microbiology and Infectious Diseases ECCMID Effective Against Most Common Pathogens Causing CRBSIs
6 1657R 1658R 1659R 1660R Please Recycle. Printed in Japan Copyright M. All Rights Reserved. HPM-442-F IT
- 1 -
- 1 - - 1 - ... 1... 2... 4... 5... 9... 11... 14... 16... 20... 21... 22... 23... 23 - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - ( ) - 10 - - 11 - Pseudomonas aeruginosa Escherichia coli Staphylococcus
ヒビスコール液A カタログ
1 2 3 2002 10 Centers for Disease Control and Prevention CDC A 1. 2. 0.2% 3. 1 A 2 3 4 5 6 7 1 1 1. 2. 3. 2 1. 1 0.2% 10 Pseudomonas aeruginosa ATCC 27853 20 20 Proteus vulgaris ATCC 13315 30 20 Escherichia
日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
Acecide_ProductsInformation2010PDF.indd
53-0115-00-4PDF 53-0115-00-4PDF INDEX 1 3 9 11 12 16 21 38 39 40 42 43 44 45 46 47 53-0115-00-4PDF 3 1 Critical Semicritical Noncritical Disinfection Sterilization 53-0115-00-4PDF 2 53-0115-00-4PDF O =
日本化学療法学会雑誌第58巻第4号
Escherichia coli Enterococcus faecalisstreptococcus agalactiae Klebsiella pneumoniae Staphylococcus epidermidis E. colie. faecalispseudomonas aeruginosa K. pneumoniae S. agalactiae E. coli E. coli μ p
ハピタス のコピー.pages
Copyright (C) All Rights Reserved. 10 12,500 () ( ) ()() 1 : 2 : 3 : 2 4 : 5 : Copyright (C) All Rights Reserved. Copyright (C) All Rights Reserved. Copyright (C) All Rights Reserved. Copyright (C) All
Copyright 2008 All Rights Reserved 2
Copyright 2008 All Rights Reserved 1 Copyright 2008 All Rights Reserved 2 Copyright 2008 All Rights Reserved 3 Copyright 2008 All Rights Reserved 4 Copyright 2008 All Rights Reserved 5 Copyright 2008 All
idwr2015_24
S. boydii S. sonnei K. pneumoniae E. aerogenes E. coli E. cloacae E. aerogenes K. pneumoniae 5 2.40 0.19 0.76 1. 1. 0.34 0.61 0.51 0.62 0.37 0.45 1.49 2SD 1SD 1SD 2SD A SD 0.17 0.77 55 1.22 4. 3.64 7.
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
公開情報 2016 年 1 月 ~12 月年報 院内感染対策サーベイランス集中治療室部門 3. 感染症発生率感染症発生件数の合計は 981 件であった 人工呼吸器関連肺炎の発生率が 1.5 件 / 1,000 患者 日 (499 件 ) と最も多く 次いでカテーテル関連血流感染症が 0.8 件 /
公開情報 2016 年 1 月 ~12 月年報 院内感染対策サーベイランス集中治療室部門 集中治療室(ICU) 部門におけるサーベイランスの概要と目的 本サーベイランスの目的は 集中治療室 (Intensive Care Unit : ICU) における人工呼吸器関連肺炎 尿路感染症 カテーテル関連血流感染症の発生状況 * を明らかにすることである 集計対象医療機関の各感染症発生率を 1,000 患者
3M_MS Guidebook_2
05 Technique Just Do It 01 Technique 02 Technique 03 Technique 04 Technique 05 Technique Just Do It 06 Technique 07 Technique 08 Technique Group B good idea innovation communication Please Recycle.
R06_01
Staphylococcus aureus (MSSA) PCG (N=118,334) 57,369 (48.5%) 判定不能 :3 (0.0%) 60,962 (51.5%) CEZ (N=143,723) I:42 (0.0%) 143,635 (99.9%) R:46 (0.0%) CVA/AMPC (N=19,281) R:14 (0.1%) 19,265 (99.9%) 判定不能 :2
初心者にもできるアメブロカスタマイズ新2016.pages
Copyright All Rights Reserved. 41 Copyright All Rights Reserved. 60 68 70 6 78 80 Copyright All Rights Reserved. FC2 97 Copyright All Rights Reserved. Copyright All Rights Reserved. Copyright All Rights
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
- 2 Copyright (C) 2006. All Rights Reserved.
- 2 Copyright (C) 2006. All Rights Reserved. 2-3 Copyright (C) 2006. All Rights Reserved. 70-4 Copyright (C) 2006. All Rights Reserved. ...1...3...7...8 1...9...14...16 2...18...20...21 3...22...23...23...24
Table 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,
1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
Copyright All Rights Reserved. -2 -!
http://ameblo.jp/admarketing/ Copyright All Rights Reserved. -2 -! Copyright All Rights Reserved. -3- Copyright All Rights Reserved. -4- Copyright All Rights Reserved. -5 - Copyright All Rights Reserved.
untitled
http://www.riskdatabank.co.jp The of Japan, Ltd. All rights reserved. 2 The of Japan, Ltd. All rights reserved. 3 The of Japan, Ltd. All rights reserved. 4 The of Japan, Ltd. All rights reserved. 5 The
Microsoft Word - 最終版 バックせどりismマニュアル .docx
ism ISM ISM ISM ISM ISM ISM Copyright (c) 2010 All Rights Reserved. Copyright (c) 2010 All Rights Reserved. Copyright (c) 2010 All Rights Reserved. ISM Copyright (c) 2010 All Rights Reserved. Copyright
４月号 学会特集号 １２２２４７／１６）一般演題目次
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 48 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 49 60 61 62 63 64 65 66 67 68
第26回日本環境感染学会総会プログラム・抄録集 Part1
26 26 26 26 26 2009 Klebsiella pneumoniae producing carbapenemasekpcmulti-drug resistant Acinetobacter baumannii MDRAbNew Delhi Metallo--Lactamase-1NDM-1 WHO CDC John BoyceDidier Pittet William RutalaCLA-BSIMark
第65回日本化学療法学会東日本支部総会 抄録
鍵 76 Clostridioides difficile C. difficile 77 γ γ Mycobacterium avium 78 79 Clostridium difficile Treponema pallidum 80 81 82 in vitro in vitro 83 鍵 Treponema pallidum 84 Chlamydia trachomatis Mycoplasma
untitled
mitsuya Copyright (C) 2007. All Rights Reserved. 1/1 mitsuya Copyright (C) 2007. All Rights Reserved. 2/2 mitsuya Copyright (C) 2007. All Rights Reserved. 3/3 mitsuya Copyright (C) 2007. All Rights Reserved.
REGZA Tabletガイド
http://toshibaplaces.jp 1 2 3 4 5 6 7 8 9 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66
健康保険組合のあゆみ_top
(1912) (1951) 2,00024,000 (1954) (1958) (1962) (1965) (1968) (1969) (1971) (1972) (1973) (1974) (1976) (1978) (1980) (1982) (1983) (1984) (1985) (1987) (1988) (1989) (1990) (1991) (1992) (1994) (1995)
CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);
VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical
日本臨床微生物学雑誌第22巻第3号
2012 STEC 231 3 STEC 1) 1) 1) 2) 2) 3) 1) 2) 3) 24 3 6 24 7 19 (Enterohemorrhagic Escherichia coli; EHEC) STEC XM-EHEC 5S A /ViEHEC O157, O26, O111 3 STEC, 14.2 100, XM-EHEC, 7.1 85.7, ViEHEC, 27.6 100
MIC MIC...
50 mg 10% 2.7.36 2.7.36 2.7.36... 1 1.6... 1 2.6... 3 3.6... 5 3.16... 5 3.26... 12 3.36... 16 4.6... 17 5.6... 19 6.6... 20 2.7.3.3.16-1 MIC... 9 2.7.3.3.16-2 MIC... 10 2.7.3.3.16-3 MIC E. coli... 11
b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
20 180pixel 180pixel Copyright 2014 Yahoo Japan Corporation. All Rights Reserved.
12 300pixel 300pixel www.yahoo.co.jp Copyright 2014 Yahoo Japan Corporation. All Rights Reserved. 20 180pixel 180pixel Copyright 2014 Yahoo Japan Corporation. All Rights Reserved. 300pixel 300pixel www.yahoo.co.jp
R01
1. 集計対象医療機関数 (1,792 医療機関 ) 13.2% (7 医療機関 ) 900 床以上 N=53 86.8% (46 医療機関 ) 19.2% (70 医療機関 ) 500 899 床 N=365 80.8% (295 医療機関 ) JANIS 参加 * 200 499 床 N=2,231 43.4% (968 医療機関 ) 56.6% (1,263 医療機関 ) JANIS 参加 200
1 2 3 4 5 6 7 a a a a a a 
c c c c c 1 c c c c c c c c c c c 2 3 c c 4 a a a a a a a a a 
Copyright 2017 JAPAN POST BANK CO., LTD. All Rights Reserved. 1
Copyright 2017 JAPAN POST BANK CO., LTD. All Rights Reserved. 1 Copyright 2017 JAPAN POST BANK CO., LTD. All Rights Reserved. 2 60 50 40 30 20 10 0 20173 20183 Copyright 2017 JAPAN POST BANK CO., LTD.
①
Copyright 2005 Impex.,inc. All Rights Reserved 1 Copyright 2005 Impex.,inc. All Rights Reserved 2 Copyright 2005 Impex.,inc. All Rights Reserved 3 Copyright 2005 Impex.,inc. All Rights Reserved 4 Copyright
% 11.1% +6.% 4, % %+12.2% 54,16 6.6% EV7, ,183 Copyright 216 JAPAN POST GROUP. All Rights Reserved. 1
216 3 216 5 13 848+4.4% 11.1% +6.% 4,853 495 +2.6% 1 +11.6%+12.2% 54,16 6.6% EV7,829 2 7,183 Copyright 216 JAPAN POST GROUP. All Rights Reserved. 1 15.3 16.3 16.3 11,692 96,57 5.5 % 4,926 4,115 16.5 %
Copyright 2008 NIFTY Corporation All rights reserved. 2
Copyright 2008 NIFTY Corporation All rights reserved. 2 Copyright 2008 NIFTY Corporation All rights reserved. 3 Copyright 2008 NIFTY Corporation All rights reserved. 4 Copyright 2008 NIFTY Corporation
P. 2 P. 4 P. 5 P. 6 P. 7 P. 9 P.10 P.12 P.13 P.14 P.14 P.15 P.17 P.18 P.20 P P P P P.25 P.27 P.28 Copyright 2016 JAPAN POST BA
201729 3 1 2016 8 12 P. 2 P. 4 P. 5 P. 6 P. 7 P. 9 P.10 P.12 P.13 P.14 P.14 P.15 P.17 P.18 P.20 P.21 10 P.22 11 P.23 12 P.24 13 P.25 P.27 P.28 Copyright 2016 JAPAN POST BANK CO., LTD. All Rights Reserved.
E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
Copyright 2006 KDDI Corporation. All Rights Reserved page1
Copyright 2006 KDDI Corporation. All Rights Reserved page1 Copyright 2006 KDDI Corporation. All Rights Reserved page2 Copyright 2006 KDDI Corporation. All Rights Reserved page3 Copyright 2006 KDDI Corporation.
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
1000 Copyright(C)2009 All Rights Reserved - 2 -
1000 Copyright(C)2009 All Rights Reserved - 1 - 1000 Copyright(C)2009 All Rights Reserved - 2 - 1000 Copyright(C)2009 All Rights Reserved - 3 - 1000 Copyright(C)2009 All Rights Reserved - 4 - 1000 Copyright(C)2009
CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
第82 回日本感染症学会総会学術集会後抄録（II）
Corydoras sterbai Kryptopterus bicirrhis Petitella georgiae Xiphophorus maculatus rpob Xba Mycobacterium szulgai Mycobacterium gordonae M. szulgai M. gordonae M. avium M. szulgai M. gordonae M. szulgai
! Copyright 2015 sapoyubi service All Rights Reserved. 2
! Copyright 2015 sapoyubi service All Rights Reserved. 2 ! Copyright 2015 sapoyubi service All Rights Reserved. 3 Copyright 2015 sapoyubi service All Rights Reserved. 4 ! Copyright 2015 sapoyubi service
report03_amanai.pages
-- Monthly Special Interview 03 COPYRIGHT 2015 NBC. ALL RIGHTS RESERVED. 1 COPYRIGHT 2015 NBC. ALL RIGHTS RESERVED. 2 COPYRIGHT 2015 NBC. ALL RIGHTS RESERVED. 3 COPYRIGHT 2015 NBC. ALL RIGHTS RESERVED.
report05_sugano.pages
- - Monthly Special Interview 05 COPYRIGHT 2015 NBC. ALL RIGHTS RESERVED. 1 COPYRIGHT 2015 NBC. ALL RIGHTS RESERVED. 2 COPYRIGHT 2015 NBC. ALL RIGHTS RESERVED. 3 COPYRIGHT 2015 NBC. ALL RIGHTS RESERVED.
概要 (2006 年 1 2 3 月分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動 向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 2005 年 2006 年 10~12
概要 (2004 年分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 ( ) 内は施設数 2002 年 2003 年 2004
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
- 2 Copyright (C) 2009. All Rights Reserved.
- 2 Copyright (C) 2009. All Rights Reserved. - 3 Copyright (C) 2009. All Rights Reserved. - 4 Copyright (C) 2009. All Rights Reserved. - 5 Copyright (C) 2009. All Rights Reserved. - 6 Copyright (C) 2009.
dekiru_asa
11 10 4 4 1 2 3 4 2 4 6 10 12 16 20 2 1 3 1 4 2 5 2 6 3 3 7 8 9 3 3 10 4 1 11 4 2 3 4 5 1 2 3 12 4 5 5 13 14 6 7 8 9 10 11 5 15 6 1 2 3 16 17 1 2 3 6 18 1 2 3 19 6 6 1 2 v 3 20 7 1 2 3 1 7 21 22 2 3 4
Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
04-c-„FŒ{›xŒ¾-4.01
544( 56 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 2. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 545( 57 ) 9 5 2003 8 2004 714 565 719 50 20 39 0 9 70 79 44.4 91.7% Escherichia coli
Fig. 1 Chemical structure of KW-1070
Fig. 1 Chemical structure of KW-1070 Fig. 2 Sensitivity distribution of clinical isolates Fig. 4 Sensitivity distribution of clinical isolates Fig. 3 Sensitivity distribution of clinical isolates Fig.